

PUBBLICAZIONI SCIENTIFICHE 2023 DEL CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO

	TITOLO PAPER	AUTORI	RIVISTA	ANNO	VOLUME	ISSUE	PAGINE		DOI	TIPO DI PUBBLICAZIONE
1	Prospective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication.	Paul H, Berg V, Gangadharan BM, Bowen J, LeBeau P, Blatny J, Male C, Radulescu V, Diaz R, Mancuso ME, Brown DL, Reipert BM.	Blood Advances	2023	7	9	1831	1848	10.1182/bloodadvances.2022007267	Trial NO PROFIT
2	Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination.	Valsecchi C, Gualtierotti R, Arcudi S, Ciavarella A, Schiavone L, Novembrino C, Siboni SM, Mannucci PM, Peyvandi F.	Blood Advances	2023	7	1	174	177	10.1182/bloodadvances.2022008989	Lettera con dati
3	The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review.	Boccalandro EA, Begnozzi V, Garofalo S, Pasca S, Peyvandi F.	Haemophilia	2023	29	1	11	20	10.1111/hae.14661	Review/linee Guida
4	Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.	Schmitt C, Mancuso ME, Chang T, Podolak-Dawidziak M, Petry C, Sidonio R Jr, Yoneyama K, Key NS, Niggli M, Lehle M, Peyvandi F, Oldenburg J.	Haemophilia	2023	29	1	90	99	10.1111/hae.14679	Articolo originale
5	Prescription appropriateness of anticoagulant drugs for prophylaxis of venous thromboembolism in hospitalized multimorbid older patients.	Rossio R, Mandelli S, Ardoino I, Nobili A, Peyvandi F, Mannucci PM, Franchi C, REPOSI collaborators.	Internal and Emergency Medicine	2023	18	1	97	104	10.1007/s11739-022-03121-7	Multicentrico NO PROFIT
6	Hemostasis from Bench to Bedside: The History of Three Successful Stories of Translational Medicine	Tripodi A.	Seminars in Thrombosis and Hemostasis	2023	49	3	234	241	10.1055/s-0042-1758060	Review/linee Guida
7	Efficacy of Lanadelumab in angioedema due to acquired C1 inhibitor deficiency	Suffritti C, Sartorio S, Berra S, Janu VP, Caccia S, Zanichelli A	Journal of Allergy and Clinical Immunology-In Practice	2023	11	3	963	965.e1	10.1016/j.jaip.2022.10.041	Lettera con dati
8	Complement activation predicts negative outcomes in COVID-19: The experience from Northern Italian patients	Meroni PL, Croci S, Lonati PA, Pregnolato F, Spaggiari L, Besutti G, Bonacini M, Ferrigno I, Rossi A, Hetland G, Hollan I, Cugno M, Tedesco F, Borghi MO, Salvarani C.	Autoimmunity Reviews	2023	22	1			10.1016/j.autrev.2022.103232	Articolo originale
9	IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.	Tagliaferri A, Molinari AC, Peyvandi F, Coppola A, Demartis F, Biasoli C, Borchiellini A, Cultrera D, De Cristofaro R, Daniele F, Giordano P, Marchesini E, Margaglione M, Marino R, Pollio B, Radossi P, Santoro C, Santoro RC, Siragusa S, Sottillotta G, Tosetto A, Piscitelli L, Villa MR, Zanon E, Finardi A, Schiavetti I, Vaccari D, Castaman G	Haemophilia	2023	29	1	135	144	10.1111/hae.14689	Trial NO PROFIT
10	Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists.	Miesbach W, Foster GR, Peyvandi F.	Journal of Hepatology	2023	78	3	467	470	10.1016/j.jhep.2022.11.014	Commento/editoriale di commento
11	Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients	Cicco S, D'Abbondanza M, Proietti M, Zaccone V, Pes C, Caradio F, Mattioli M, Piano S, Marra AM, Nobili A, Mannucci PM, Pietrangelo A, Sesti G, Buzzetti E, Salzano A, Cimellaro A; Giovani Internisti Società Italiana di Medicina Interna (GIS-SIM) and of the REPOSI Investigators (Peyvandi F, Rossio R, Agosti P).	European Journal of Clinical Investigation	2023	53	4			10.1111/eci.13931.	Multicentrico NO PROFIT
12	Air Pollution and Cardiovascular Health in Middle East and North Africa: Many Shadows but Some Light.	Mannucci PM, Peyvandi F.	European Journal of Preventive Cardiology	2023	30	3	254	255	10.1093/eurjpc/zwac292	Editoriale
13	Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.	Filtz A, Carandina A, Fasiello A, Barbeta L, Lombardi R, Cinque F, Rizzi G, Ceriani E, Furlan L, Bellocchi C, Fracanzani AL, Hu C, Cogliati C, Canetta C, Peyvandi F, Montano N, Tobaldini E.	Internal and Emergency Medicine	2023	18	2	359	366	10.1007/s11739-022-03168-6	Articolo originale
14	Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience.	Trisolini SM, Capria S, Artoni A, Mancini I, Biglietto M, Gentile G, Peyvandi F, Testi AM.	Haematologica	2023	108	7	1957	1959	10.3324/haematol.2022.282311	Lettera con dati
15	A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.	Zanon E, Pasca S, Sottillotta G, Molinari AC, Ferretti A, Di Gregorio P, Pollio B, Pizzuti M, Notarangelo LD, Biasoli C, Cojutti P, Pea F, Simioni P, Peyvandi F.	Blood Transfusion	2023	21	4	350	355	10.2450/2022.0121-22	Multicentrico NO PROFIT
16	A retrospective study on the use of low-molecular-weight heparin for prevention of pregnancy-related recurrent venous thromboembolism and obstetrical complications	Abbattista M, Capecci M, Gianniello F, Artoni A, Bucciarelli P, Ciavarella A, Peyvandi F, Martinelli I.	Blood Coagulation and Fibrinolysis	2023	34	2	111	117	10.1097/MBC.00000000000001190	Articolo originale
17	Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study.	Castaman G, Carulli C, De Cristofaro R, Follino M, Lupi A, Mancuso ME, Mansueto MF, Molinari AC, Pasquetti P, Santoro C, Santoro RC, Siragusa S, Solimeno LP, Tripodi A, Zanon E, Minno GD.	Haemophilia	2023	29	2	435	444	10.1111/hae.14709	Review/linee Guida
18	The diagnostics of heparin-induced thrombocytopenia in Italy and the possible impact of vaccine-induced immune thrombotic thrombocytopenia on it.	Falcinelli E, Marcucci R, Gresele P, Accorsi P, Barcellona D, Contino L, D'Angelo A, De Cristofaro R, Di Gregorio P, Falanga A, Gandini G, Grandone E, Guglielmini G, La Raja M, Mameli LA, Martini G, Montaruli B, Napolitano M, Pecci A, Podda GM, Pulcinelli F, Ranieri P, Russo T, Santagada D, Santer P, Santoro R, Testa S, Tosetto A, Tripodi A, Valpreda A.	Clinical Chemistry and Laboratory Medicine	2023	61	6	e91	e95	10.1515/ccim-2022-0968	Lettera con dati
19	Whole blood platelet aggregation measurement by Multiplate™: potential diagnostic inaccuracy of correcting the results for the sample platelet count.	Scavone M, Podda GM, Tripodi A, Cattaneo M.	Platelets	2023	34	1			10.1080/09537104.2022.2156493.	Lettera con dati
20	Liver Transplantation for Porto-Sinusoidal Vascular Liver Disorder: Long-term Outcome.	Magaz M, Giudicelli-Lett H, Nicoară-Fărcău O, Rajoriya N, Goel A, Raymenants K, Hillaire S, Crespo G, Téllez L, Elkrief L, Fondevila C, Orts L, Nery F, Shukla A, Larrue H, Fundora Y, Degroote H, Aguilera V, Llop E, Turco L, Indulti F, Gioia S, Tosetti G, Bitto N, Becchetti C, Alvarado E, Roig C, Diaz R, Praktijnjo M, Konicek AL, Soy G, Olivas P, Fortea JJ, Masnou H, Puente Á, Ardévol A, Álvarez-Navascués C, Romero M, Scheiner B, Semmler G, Mandorfer M, Damião F, Baiges A, Turon F, Simón-Talero M, González-Alayón C, Díaz A, García-Criado Á, de Gottardi A, Reverter E, Blasi A, Genescà J, Roux O, Francoz C, Noronha Ferreira C, Reiberger T, Rodríguez M, Morillas RM, Crespo J, Trebicka J, Bañares R, Villanueva C, Berzigotti A, Primignani M, La Mura V, Riggio O, Schepis F, Procopet B, Verhelst X, Calleja JL, Bureau C, Albillos A, Nevens F, Hernández-Gea V, Tripathi D, Rautou PE, Durand F, García-Pagán JC.	Transplantation	2023	107	6	1330	1340	10.1097/TP.0000000000000444	Multicentrico NO PROFIT
21	Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists.	Miesbach W, Foster GR, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	2	200	203	10.1016/j.jth.2022.11.026	Review/linee Guida
22	Thromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations.	Tripodi A, Scalambriano E, Clerici M, Chantarangkul V, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	2	311	316	10.1016/j.jth.2022.11.016	Articolo originale
23	Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.	Abbattista A, Ciavarella A, Noone D, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	3	546	552	10.1016/j.jth.2023.01.010	Articolo originale

24	Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.	von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group (Peyvandi F).	New England Journal of Medicine	2023	388	4	310	318	10.1056/NEJMoa2209226.	Trial Profit
25	IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab.	Maronese CA, Ferrucci SM, Moltrasio C, Lorini M, Carbonelli V, Asero R, Marzano AV, Cugno M.	Journal of Clinical Medicine	2023	12	1			10.3390/jcm12010378.	Articolo originale
26	The role of general practitioners in the EU: time to draw lessons from a too wide range?	Garattini L, Nobili A, Badinella Martini M, Mannucci PM.	Internal and Emergency Medicine	2023	18	2	343	346	10.1007/s11739-023-03205-y	Review/linee Guida
27	How we manage cardiovascular disease in patients with hemophilia.	Franchini M, Focosi D, Mannucci PM.	Haematologica	2023	108	7	1748	1757	10.3324/haematol.2022.282407	Review/linee Guida
28	Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis.	Gualtierotti R, Ruscica M.	Frontiers in Cardiovascular Medicine	2023	9				10.3389/fcvm.2022.1127693	Editoriale
29	Prevalence of hemorrhagic ovarian cysts in patients with rare inherited bleeding disorders	Seidizadeh O, Aliabad GM, Mirzaei I, Yaghoubi S, Abtin S, Valikhani A, Naderi M.	Transfusion and Apheresis Science	2023	62	3			10.1016/j.transci.2022.103636	Articolo originale
30	Recombinant Factor VIII Fc Fusion Protein for First-time Immune Tolerance Induction: Final Results of the verITI-8 Study.	Malec LD, Van Damme A, Chan AK, Spasova M, Jain N, Sensinger C, Dumont J, Lethagen S, Carcao M, Peyvandi F.	Blood	2023	141	16	1982	1989	10.1182/blood.2022017780	Trial Profit
31	Genetic determinants of enhanced von Willebrand factor clearance from plasma.	Seidizadeh O, Baronciani L, Pagliari MT, Cozzi G, Colpani P, Cairo A, Siboni SM, Biguzzi E, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	5	1112	1122	10.1016/j.jth.2023.01.012	Articolo originale
32	Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both.	Crisafulli E, Sartori G, Vianello A, Busti F, Nobili A, Mannucci PM, Girelli D; REPOSI Investigators (Peyvandi F, Rossio R, Agosti P).	Internal and Emergency Medicine	2023	18	2	523	534	10.1007/s11739-023-03207-w	Multicentrico NO PROFIT
33	von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.	Pagliari MT, Budde U, Baronciani L, Eshghi P, Ahmadinejad M, Badiee Z, Baghaipour MR, Hidalgo OB, Biguzzi E, Bodó I, Castaman G, Goudemand J, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Marino R, Oldenburg J, Peake I, Santoro C, Schneppenheim R, Tiede A, Toogeh G, Tosetto A, Trossaert M, Yadegari H, Zetterberg EMK, Mannucci PM, Federici AB, Eikenboom J, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	4	787	799	10.1016/j.jth.2023.01.001	Multicentrico NO PROFIT
34	Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients with Diabetes.	Ardoino I, Mandelli S, Baviera M, Rossio R, Nobili A, Mannucci PM, Franchi C, On Behalf Of Reposi Investigator (Peyvandi F, Rossio R, Agosti P)	International Journal of Environmental Research and Public Health	2023	20	3	2670		10.3390/ijerph20032607.	Multicentrico NO PROFIT
35	Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.	Bitto N, Ghigliazza G, Lavorato S, Caputo C, La Mura V.	Journal of Clinical Medicine	2023	12	3	934		10.3390/jcm12030934.	Review/linee Guida
36	Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.	Pasca S, Zanon E, Mannucci PM, Peyvandi F.	Blood Transfusion	2023	21	6	549	556	10.2450/2023.0247-22	Review/linee Guida
37	Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran.	Agosti P, Mancini I, Sadeghian S, Pagliari MT, Abbasi SH, Pourhosseini H, Boroumand M, Lotfi-Tokaldany M, Pappalardo E, Maino A, Rosendaal FR, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	1			10.1016/j.rpth.2023.100048	Articolo originale
38	Viscoelastic coagulation testing in Neonatal Intensive Care Units: advantages and pitfalls in clinical practice.	Manzoni F, Raffaelli G, Cortesi V, Amelio GS, Amodeo I, Gulden S, Cervellini G, Tomaselli A, Colombo M, Artoni A, Ghirardello S, Mosca F, Cavallaro G.	Blood Transfusion	2023	21	6	538	548	10.2450/2023.0203-22	Review/linee Guida
39	Intravenous immunoglobulins in autoimmune cytopenias: an old tool with an alternative dosing schedule.	Giannotta JA, Capecci M, Fattizzo B, Artoni A, Barcellini W.	Blood Transfusion	2023	21	6	557	560	10.2450/2023.0228-22	Articolo originale
40	Two-Year Outcomes of Valoctocogene Roxaparvec Therapy for Hemophilia A.	Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DV, Symington E, Leavitt AD, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele KM, Reddy DB, Henshaw J, Robinson TM, Wong WY, Pipe SW; GENE8-1 Trial Group.	New England Journal of Medicine	2023	388	8	694	705	10.1056/NEJMoa2211075	Trial Profit
41	Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post hoc analysis from a phase 3 trial.	Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, Zülfikar B, Susen S, Miesbach W, Wang S, Wang Y, Zhang J, Özen G.	European Journal of Haematology	2023	111	1	29	40	10.1111/ejh.13949	Trial Profit
42	Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs.	Castaman G, Peyvandi F, De Cristofaro R, Pollio B, Di Minno DMN.	Journal of Clinical Medicine	2023	12	4			10.3390/jcm12041368.	Editoriale
43	Hemophilia treatment innovation: 50 years of progress and more to come.	Mannucci PM.	Journal of Thrombosis and Haemostasis	2023	21	3	403	412	10.1016/j.jth.2022.12.029	Review/linee Guida
44	Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.	Guerrero A, Campo LD, Piscaglia F, Scheiner B, Han G, Violi F, Ferreira CN, Téllez L, Reiberger T, Basili S, Zamora J, Albillos A; Baveno Cooperation: an EASL consortium (La Mura V).	Journal of Hepatology	2023	79	1	69	78	10.1016/j.jhep.2023.02.02	Multicentrico Collaborators
45	Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura.	Cugno M, Mancini I, Consonni D, De Zan V, Ardisino G, Griffini S, Grovetti E, Porcaro L, Ferrari B, Artoni A, Peyvandi F.	Blood	2023	141	18	2278	2282	10.1182/blood.2022018644	Lettera con dati
46	Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review.	Shapiro AD, Hardesty BM, Peyvandi F, Iorio A.	Research and Practice in Thrombosis and Haemostasis	2023	7	1			10.1016/j.rpth.2022.100007.	Review/linee Guida
47	Effect of Physical Activity Intervention on Gait Speed by Frailty Condition: A Randomized Clinical Trial	Custodero C, Agosti P, Anton SD, Manini TM, Lozupone M, Panza F, Pahor M, Sabbà C, Solfrizzi V.	Journal of the American Medical Directors Association	2023	24	4	489	496	10.1016/j.jamda.2023.01.023	Trial NO PROFIT
48	Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies.	Mohsenian S, Seidizadeh O, Palla R, Jazebi M, Azarkeivan A, Moazezi S, Baghaipour MR, Menegatti M, Peyvandi F.	Haemophilia	2023	29	3	827	835	10.1111/hae.14773.	Articolo originale
49	The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants.	Tripodi A, Chantarangkul V, Poli D, Testa S, Bucciarelli P, Peyvandi F.	Thrombosis Research	2023	225	/	11	15	10.1016/j.thromres.2023.01.030.	Articolo originale
50	Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.	Capecci M, De Leo P, Abbattista M, Mancini I, Agosti P, Biganzoli M, Suffritti C, Ferrari B, Lecchi A, La Marca S, Padovan L, Scalabrino E, Clerici M, Tripodi A, Artoni A, Gualtierotti R, Peyvandi F.	Haematologica	2023	108	11	3152	3155	10.3324/haematol.2022.282478	Lettera con dati
51	Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register.	Succurro E, Novella A, Nobili A, Giorfé F, Arturi F, Sciacqua A, Andreozzi F, Pietrangelo A, Sesti G; REPOSI Investigators (Peyvandi F, Rossio R, Agosti P).	Internal and Emergency Medicine	2023	18	4	1049	1063	10.1007/s11739-023-03254-3.	Multicentrico Collaborators
52	Fitusiran in haemophilia: a breakthrough drug with many unknowns.	Peyvandi F, Garagiola I, Abbattista M.	Lancet	2023	401	10386	1400	1401	10.1016/S0140-6736(23)00514-7.	Commento/editoriale di commento

53	Low serum albumin is associated with mortality and arterial and venous ischemic events in acutely ill medical patients. Results of a retrospective observational study.	Violi F, Novella A, Pignatelli P, Castellani V, Tettamanti M, Mannucci PM, Nobili A; REPOSI (Registro POLiterapie SIMI), Società Italiana di Medicina Interna) Study Group (Peyvandi F, Rossio R, Agosti P).	Thrombosis Research	2023	225	/	1	10	10.1016/j.thromres.2023.02.013	Multicentrico NO PROFIT
54	Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact.	Nobili A, D'Avanzo B, Tettamanti M, Galbusera AA, Remuzzi G, Fortino I, Leoni O, Harari S, Mannucci PM.	Internal and Emergency Medicine	2023	18	3	801	809	10.1007/s11739-023-03228-5	Articolo originale
55	Conceptualizing a model for European health systems: the institutional framework.	Garattini L, Freemantle N, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2023	18	4	1213	1215	10.1007/s11739-023-03261-4	Articolo originale
56	Age of onset of cerebral venous thrombosis: the BEAST study.	Ranjan R, Ken-Dror G, Martinelli I, Grandone E, Hiltunen S, Lindgren E, Margaglione M, Le Cam Duchez V, Bagan Triquetot A, Zedde M, Mancuso M, Ruigrok YM, Worrall B, Majersik JJ, Putaala J, Haapaniemi E, Zuurbier SM, Brouwer MC, Passamonti SM, Abbattista M, Bucciarelli P, Lemmens R, Pappalardo E, Costa P, Colombi M, Aguiar de Sousa D, Rodrigues S, Canhao P, Tkach A, Santacrose R, Favuzzi G, Arauz A, Colaizzo D, Spengos K, Hodge A, Ditta R, Han TS, Pezzini A, Coutinho JM, Thijs V, Jood K, Tatlisumak T, Ferro JM, Sharma P.	European Stroke Journal	2023	8	1	344	350	10.1177/23969873221148267	Multicentrico NO PROFIT
57	Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients.	Reipert BM, Hofbauer CJ, Gangadharan B, Berg V, Donnachie E, Meeks S, Mancuso ME, Bowen J, Brown DL.	Journal of Clinical Medicine	2023	12	5			10.3390/jcm12052080.	Articolo originale
58	Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.	Turco L, Reiberger T, Vitale G, La Mura V.	Liver International	2023	43	6	1183	1194	10.1111/liv.15559.	Review/linee Guida
59	Opium as a risk factor for early-onset coronary artery disease: Results from the Milano-Iran (Miran) study.	Maino A, Sadeghian S, Mancini I, Abbasi SH, Poorhosseini H, Boroumand MA, Lotfi-Tokaldany M, Jalali A, Pagliari MT, Rosendaal FR, Peyvandi F.	Plos One	2023	18	4			10.1371/journal.pone.0283707.	Articolo originale
60	Air pollution, cardiovascular disease and urban greening: an ecological blueprint.	Mannucci PM	European Journal of Preventive Cardiology	2023	30	15	1608	1611	10.1093/eurjpc/zwad119	Review/linee Guida
61	[Hemophilia therapy in Italy: what the near future promises.]	Mannucci PM	Recenti Progressi in Medicina	2023	114	5	247	249	10.1701/4032.40071.	Commento/editoriale di commento
62	Recombinant FVIII: the milestone of modern hemophilia treatment.	Mannucci PM	Haematologica	2023	108	5	1201	1202	10.3324/haematol.2023.282874.	Editoriale
63	Use of total thrombus-formation analysis system in detecting acquired platelet function defects: A case report.	Boggio F, Lecchi A, La Marca S, Padovan L, Galdaniga M, Caccioppola A, Artoni A.	International Journal of Laboratory Hematology	2023	45	5	802	805	10.1111/ijlh.14083.	Lettera con dati
64	Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?	Asero R, Ferrucci SM, Calzari P, Consonni D, Cugno M.	International Journal of Molecular Sciences	2023	24	8			10.3390/ijms24087491.	Articolo originale
65	A European national health and social service model: a few rules of the game.	Garattini L, Freemantle N, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2023	18	5	1583	1585	10.1007/s11739-023-03301-z	Articolo originale
66	Laboratory Testing for von Willebrand Factor Activity by a Glycoprotein Ib-Binding Assay (VWF:GPIbR): HemoSIL von Willebrand Factor Ristocetin Cofactor Activity on ACL TOP®	Seizideh O, Peyvandi F.	Methods in Molecular Biology	2023	2663		669	677	10.1007/978-1-0716-3175-1_44.	Review/linee Guida
67	A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays.	Colpani P, Baronciani L, Stufano F, Cozzi G, Boscarino M, Pagliari MT, Biguzzi E, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	3			10.1016/j.rpth.2023.100139	Articolo originale
68	International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors.	Meijer P, Peyvandi F, Young G, Pruthi R, de Lima Montalvão S, Kitchen S.	International Journal of Laboratory Hematology	2023	45	4	413	424	10.1111/ijlh.14109	Review/linee Guida
69	Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes.	Agno W, Antonucci E, Poli D, Bucherini E, Chistolini A, Fregoni V, Lerede T, Pancani R, Pedrini S, Pieralli F, Pignatelli P, Pizzini AM, Podda GM, Potere N, Sarti L, Testa S, Visonà A, Palareti G; START 2 Registry VTE study group (Martinelli I, Bucciarelli P, Abbattista M).	Research and Practice in Thrombosis and Haemostasis	2023	7	4			10.1016/j.rpth.2023.100167.	Multicentrico Collaborators
70	Sustainable nutrition and the case of vegetable oils to match present and future dietary needs.	Mannucci PM, Joliet O, Meijaard E, Slavina J, Rasetti M, Aleta A, Moreno Y, Agostoni C.	Frontiers in Public Health	2023	11	//			10.3389/fpubh.2023.1106083.	Review/linee Guida
71	Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders.	Nugent D, Acharya SS, Baumann KJ, Bedrosian C, Bialas R, Brown K, Corzo D, Haidar A, Hayward CPM, Marks P, Menegatti M, Miller ME, Nammacher K, Palla R, Peltier S, Pruthi RK, Recht M, Sørensen B, Tarantino M, Wolberg AS, Shapiro AD.	Expert Review of Hematology	2023	16	Suppl1	55	70	10.1080/17474086.2023.2175661	Articolo originale
72	Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients.	Gualtierotti R, Fox SE, Da Silva Lameira F, Giachi A, Valenti L, Borghi MO, Meroni PL, Cugno M, Peyvandi F, On Behalf Of The Capcovid Study Group.	Journal of Clinical Medicine	2023	12	11			10.3390/jcm12113727.	Multicentrico NO PROFIT
73	"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists": reply.	Miesbach W, Foster GR, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	7	2000	2001	10.1016/j.jtha.2023.04.011	Lettera con dati
74	Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients.	Tripodi A, Scalabrino E, Clerici M, Peyvandi F.	Biomedicines	2023	11	6	1760		10.3390/biomedicines11061760.	Review/linee Guida
75	Bilirubin color interference on prothrombin time and activated partial thromboplastin time tests assessed in patients with liver disease.	Scalabrino E, Faioni EM, Clerici M, Avarello I, Capecci M, Pasca S, Tripodi A.	Clinical Chemistry and Laboratory Medicine	2023	61	12	e244	e247	10.1515/cclm-2023-0393.	Lettera con dati
76	The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease.	Swan D, Lisman T, Tripodi A, Thachil J.	Journal of Thrombosis and Haemostasis	2023	21	11	3045	3055	10.1016/j.jtha.2023.06.017	Review/linee Guida
77	Exploring the prevalence and clinical impact of fibromyalgia syndrome in patients with shoulder diseases: a cross-sectional study.	Compagnoni R, Suffritti C, Fossati C, Zanini B, Gerace F, Menon A, Randelli PS, Gualtierotti R.	Clinical and Experimental Rheumatology	2023	41	6	1317	1322	10.55563/clinexrheumatol/rf0z54.	Articolo originale
78	Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review.	Mannucci PM, Kessler CM, Germini F, Nissen F, Ofori-Asenso R, Brocchieri C, Bendinelli S, Iorio A.	Haemophilia	2023	29	4	954	962	10.1111/hae.14803	Systematic Review
79	Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy.	Mannucci PM, Galbusera AA, D'Avanzo B, Tettamanti M, Remuzzi G, Fortino I, Leoni O, Harari S, Nobili A.	Internal and Emergency Medicine	2023	18	5	1445	1451	10.1007/s11739-023-03315-7	Articolo originale
80	A European national health and social service model: a rational network of health care facilities	Garattini L, Badinella Martini M, Freemantle N, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2023	18	6	1855	1857	10.1007/s11739-023-03342-4	Lettera opinion
81	A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma.	Piscaglia F, La Mura V, Ravaoli F.	Digestive and Liver Disease	2023	55	8	997	1000	10.1016/j.dld.2023.05.017	Lettera con dati

82	"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists": reply.	Miesbach W, Foster GR, Peyvandi F.	Journal of Thrombosis and Haemostasis	2023	21	8	2307	2308	10.1016/j.jtha.2023.04.030	Commento/editoriale di commento
83	Laboratory investigation and diagnosis of thrombotic thrombocytopenic purpura.	Dimopoulos K, Tripodi A , Goetze JP.	Critical Reviews in Clinical Laboratory Sciences	2023	60	8	625	639	10.1080/10408363.2023.232039.	Review/linee Guida
84	Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.	La Mura V, Bitto N , Capelli C, Caputo C, Siboni SM, Arcudi S, Ciavarella A, Gualtierotti R , Fracanzani AL, Sangiovanni A, Peyvandi F.	Blood Advances	2023	7	19	5817	5824	10.1182/bloodadvances.2023010723.	Articolo originale
85	Hemophilia patients: are they naturally anticoagulated?	Tripodi A, Mannucci PM, Peyvandi F.	Internal and Emergency Medicine	2023	18	5	1251	1254	10.1007/s11739-023-03331-7	Systematic Review
86	Anemia management and transfusion strategy in internal medicine units: Less is more.	Blanca D, Parrella G, Consonni D, Villa S, Ceriani G, Cespiati A, Figini G, Ghigliazza G, Maira D, Oberti G, Scaramellini N, Schinco GL, Tafuri F , Montano N, Cappellini MD, Motta I.	European Journal of Internal Medicine	2023	115	//	54		10.1016/j.ejim.2023.05.022	Articolo originale
87	Undiagnosed cognitive impairment in older adults hospitalized in internal medicine wards: Data from the REPOSI registry.	Agosti P , Novella A, Custodero C, Elli C, Pasina L; REPOSI Investigators (Peyvandi F, Rossio R, Mannucci PM).	European Journal of Internal Medicine	2023	117	/	129	133	10.1016/j.ejim.2023.07.030.	Lettera con dati
88	Psychological and cognitive factors involved in decision-making process of haemophilia carriers in reproductive choices.	Cutica I, Mortarino M, Garagiola I , Pravettoni G, Peyvandi F.	Haemophilia	2023	29	5	1313	1319	10.1111/hae.14836	Articolo originale
89	Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline.	Di Minno G, Spadarella G, Maldonato NM, De Lucia N, Castaman G, De Cristofaro R, Santoro C, Peyvandi F , Borrelli A, Lupi A, Follino M, Guerrino G, Morisco F, Di Minno M.	Blood Reviews	2023	62	November 2023			10.1016/j.blre.2023.101118	Review/linee Guida
90	Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.	Kessler CM, Corrales-Medina FF, Mannucci PM , Jiménez-Yuste V, Tarantino MD.	European Journal of Haematology	2023	111	5	757	767	10.1111/ejh.14073	Articolo originale
91	"The ISTH SSC subcommittee on hemostatic management of patients with liver disease: goals, ambitions, and call for collaboration": comment.	Tripodi A, Mannucci PM.	Journal of Thrombosis and Haemostasis	2023	21	9	2630	2631	10.1016/j.jtha.2023.05.017.	Commento/editoriale di commento
92	To be or NOD 2 be: The role of NOD2 in predisposing patients with cirrhosis towards infections.	Fischer J, La Mura V , Trebicka J	Digestive and Liver Disease	2023	55	10	1360	1361	10.1016/j.dld.2023.07.030	Commento/editoriale di commento
93	Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.	Sidonio RF Jr, Thompson AA, Peyvandi F , Stasyshyn O, Yeoh SL, Sosothikul D, Antmen AB, Maggiore C, Engl W, Ewenstein B, Tangada S.	Expert Review of Hematology	2023	16	10	793	801	10.1080/17474086.2023.247160	Trial Profit
94	A second update on mapping the human genetic architecture of COVID-19.	COVID-19 Host Genetics Initiative (Peyvandi F)	Nature	2023	621	7977	E7	E26	10.1038/s41586-023-06355-3	Lettera con dati
95	Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENER8-1.	O'Mahony B, Dunn AL, Leavitt AD, Peyvandi F , Ozelo MC, Mahlangu J, Peerlinck K, Wang JD, Lowe GC, Tan CW, Giermasz A, Tran H, Khoo TL, Cockrell E, Pepperell D, Chambost H, López Fernández MF, Kazmi R, Majerus E, Skinner MW, Klamroth R, Quinn J, Yu H, Wong WY, Robinson TM, Pipe SW.	Journal of Thrombosis and Haemostasis	2023	21	12	3450	3462	10.1016/j.jtha.2023.08.032	Trial Profit
96	Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study.	Suffritti C, Gualtierotti R, Arcudi S, Ciavarella A, Novembrino C, Lecchi A, La Marca S, Padovan L, Scalabrino E, Clerici M, Bono P, Ceriotti F, Muscatello A, Siboni SM, Peyvandi F.	Journal of Clinical Medicine	2023	12	7			10.3390/jcm12175475.	Articolo originale
97	Anti-emizumab antibodies do not cross-react with mim8 in vitro.	Valsecchi C, Gualtierotti R, Arcudi S, Ciavarella A, Siboni SM, Schiavone I , Beeg M, Gobbi M, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	6			10.1016/j.rpth.2023.102161.	Lettera con dati
98	Post-recovery impact of the second and third SARS-CoV-2 infection waves on healthcare resource utilization in Lombardy, Italy.	Harari S, Mannucci PM , Nobili A, Galbusera AA, Fortino I, Leoni O, Remuzzi G, D'Avanzo B, Tettamanti M.	Internal and Emergency Medicine	2023	18	7	2011	2018	10.1007/s11739-023-03396-4	Multicentrico NO PROFIT
99	A European national health and social service model: imagining a rational philosophy for health care organizations.	Garattini L, Badinella Martini M, Freemantle N, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2023	18	8	2435	2437	10.1007/s11739-023-03409-2	Lettera opinion
100	Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.	Agosti P, De Leo P, Capecci M, Ferrari B, Mancini I , Gattillo S, Trisolini SM, Rinaldi E, Podda GM, Prezioso L, Salutari P, Facchini L, Caramazza D, Tolomelli G, Artoni A, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	6			1016/j.rpth.2023.102185	Lettera con dati
101	Reply to "Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays".	Colpani P, Baronciani L, Cozzi G, Pagliari MT, Biguzzi E, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	6			10.1016/j.rpth.2023.102174	Lettera con dati
102	The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic.	Canuti M, Monti MC, Bobbio C, Muscatello A, Muheberimana T, Baldi SL, Blasi F, Canetta C, Costantino G, Nobili A, Peyvandi F , Tettamanti M, Villa S, Aliberti S, Raviglione MC, Gori A, Bandera A; COVID-19 Network Study Group (Gualtierotti R, Ferrari B, Rossio R).	Frontiers in Medicine (Lausanne)	2023	10				10.3389/fmed.2023.1260950.	Multicentrico NO PROFIT
103	Genetic Variants Identified by Whole Exome Sequencing in a Large Italian Family with High Plasma Levels of Factor VIII and Von Willebrand Factor.	Spena S, Cairo A, Giannello F, Pappalardo E, Mortarino M, Garagiola I, Martinelli I, Peyvandi F.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2023	24	18			10.3390/ijms241814167.	Articolo originale
104	Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy.	Boban A, Baghaei F, Karin F, Klamroth R, Miesbach W, Stephensen D, Kavanagh M, Noone D, Crato M, Peyvandi F; EAHAD Accreditation and Audit of Haemophilia Centres Working Group.	Haemophilia	2023	29	6	1442	1449	10.1111/hae.14887	Multicentrico NO PROFIT
105	Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases.	Seidzadeh O, Cairo A, Baronciani L, Valenti L, Peyvandi F.	NPJ Genomic Medicine	2023	8	1			10.1038/s41525-023-00375-8.	Articolo originale
106	Guidance for the antithrombotic management of persons with haemophilia and cardiovascular disease.	Mannucci PM, Agosti P , Lettino M.	Haemophilia	2023	29	6	1390	1393	10.1111/hae.14874	Commento/editoriale di commento
107	Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.	Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Aygusanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group (Artoni A).	Lancet	2023	402	10413	1648	1659	10.1016/S0140-6736(23)01460-5	Trial Profit
108	Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A.	Agosti P, Siboni SM, Scardo S, Torri A, Gualtierotti R, Peyvandi F.	Blood Advances	2023	7	23	7209	7215	10.1182/bloodadvances.2023011366	Articolo originale

109	Joint Dysfunction as a Cause of Spontaneous Subclinal Bleeding in Infants with Hemophilia.	Boccalandro EA, Pasca S, Begnozzi V, Gualtierotti R, Mannucci PM.	Journal of Clinical Medicine	2023	12	20			10.3390/jcm12206672.	Review/linee Guida
110	Ligneous conjunctivitis and use of human plasminogen eyedrops: The Italian experience	Sartori MT, Bartuli A, Siboni SM , Leonardi A, Valente P, Secci J, Cortellessa F, Caputo R.	Haemophilia	2023	29	2	681	684	10.1111/hae.14745	Lettera con dati
111	Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab	Novembrino C, Boscolo-Anzoletti M, Galbiati E, Shinohara S, Peyvandi F.	Research and Practice in Thrombosis and Haemostasis	2023	7	8			10.1016/j.rpth.2023.102260	Articolo originale
112	COVID-19. Comparison of D-dimer levels measured with 3 commercial platforms	Scalambrino E, Clerici M, Scardo S, Capecci M, Della Noce C, Testa S, Peyvandi F, Tripodi A.	Research and Practice in Thrombosis and Haemostasis	2023	7	8			10.1016/j.rpth.2023.102247	Lettera con dati
113	Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada	Fischer K, Lassila R, Peyvandi F , Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettle A, Samji N, Rivard G-É, Carcao M, Iorio A, Makris M, on behalf of the EUHASS and CHES participants	Research and Practice in Thrombosis and Haemostasis	2023	7	8			10.1016/j.rpth.2023.102265	Multicentrico NO PROFIT
114	Ultrasound detection of subquadrilateral recess distension	Colussi M, Civitarese G, Ahmetovic D, Bettini C, Gualtierotti R, Peyvandi F , Mascetti S.	Intelligent Systems with Applications	2023	17				10.1016/j.iswa.2023.200183	Articolo originale
115	Pollution from fine particulate matter and atherosclerosis: A narrative review	Macchi C, Sirtori C.R, Corsini A, Mannuccio Mannucci P , Ruscica M.	Environment International	2023	175				10.1016/j.envint.2023.107923	Review/linee Guida
116	Is non-alcoholic fatty liver disease a prothrombotic risk factor?	Bitto N, La Mura V, Fracanzani AL, Tripodi A,	Bleeding, Thrombosis and Vascular Biology	2023	2	2			https://doi.org/10.4081/bt.vb.2023.81	Editoriale
117	Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case-control study	Deltenre P, Payancé A, Elkrief L, La Mura V , Artru F, Baiges A, Cervoni JP, China L, Colle I, Lemaître E, Bogdan Procopet B, Schiller D, Bureau C, Gorla O, Olivier I, Nuzzo A, Rautou PE, Plessier A; for VALDIG, an EASL consortium (Bitto N)	Journal of Hepatology Report	2023	5	11	100894		10.1016/j.jhepr.2023.100894	Multicentrico NO PROFIT